Cardiovascular Safety of Long-term Use of Biologic Therapies: A MetaAnalysis of Clinical Trials
Received Date: Dec 01, 2024 / Published Date: Dec 31, 2024
Abstract
Abstract This meta-analysis examines the cardiovascular safety of long-term biologic therapy use across various autoimmune and inflammatory conditions. Through systematic review and analysis of clinical trial data, we investigate the incidence of cardiovascular events, including myocardial infarction, stroke, and heart failure, among patients receiving biologic therapies compared to controls. Despite concerns regarding the potential cardiovascular risks associated with chronic inflammation and biologic therapy use, our comprehensive analysis reveals no significant increase in cardiovascular events with long-term biologic therapy use. These findings offer reassurance regarding the cardiovascular safety of biologic therapies in the management of autoimmune and inflammatory conditions, though ongoing monitoring and comprehensive cardiovascular risk management remain essential.
Citation: Dominic A (2024) Cardiovascular Safety of Long-term Use of BiologicTherapies: A Meta-Analysis of Clinical Trials. World J Pharmacol Toxicol 7: 249.
Copyright: © 2024 Dominic A. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Share This Article
天美传媒 Access Journals
Article Usage
- Total views: 312
- [From(publication date): 0-2024 - Jan 10, 2025]
- Breakdown by view type
- HTML page views: 273
- PDF downloads: 39
